Dr. Jianfeng Shen is an accomplished researcher and assistant professor at Shanghai Jiao Tong University School of Medicine, with expertise in cancer biology, chromatin remodeling, and DNA damage response. Holding a Ph.D. from the Chinese Academy of Sciences, Dr. Shen has a dedicated focus on unraveling the complexities of cancer biology to identify novel therapeutic strategies.
Author Metrics:
Dr. Shen’s contributions have garnered recognition, evident in his author metrics. His publications have received citations, and his research has contributed to the scientific community’s understanding of cancer biology and therapeutic approaches.
Citations: 1,650
Documents: 36
h-index: 14
Author Metrics Summary: Dr. Jianfeng Shen, affiliated with Shanghai Jiao Tong University School of Medicine, has a substantial academic impact with 1,650 citations across 36 documents. His h-index, a measure of both productivity and citation impact, stands at 14. This signifies that Dr. Shen has published 36 papers, each of which has been cited at least 14 times.
Scopus Profile
Orcid Profile
Education:
Dr. Shen holds a Ph.D. in Biochemistry and Molecular Biology from the Chinese Academy of Sciences, Shanghai Institutes for Biological Sciences (SIBS), earned between 2005 and 2010. Prior to his Ph.D., he completed his Bachelor of Science in Biotechnology at Zhejiang University, College of Life Science, from 2001 to 2005.
Research Focus:
Dr. Shen’s research revolves around understanding key mechanisms in cancer biology, specifically the impact of chromatin remodeling and DNA damage response on anti-tumor immunity. His commitment lies in advancing our comprehension of immune evasion mechanisms resulting from deficiencies in DNA damage repair machinery and developing strategies to exploit cancer-specific vulnerabilities.
Professional Journey:
Currently serving as a Principal Investigator and Assistant Professor at Shanghai Jiao Tong University School of Medicine since March 2019, Dr. Shen has a rich professional history. Before his current position, he served as a Postdoctoral Research Fellow and Instructor at The University of Texas M.D. Anderson Cancer Center in Houston, Texas, from November 2012 to February 2019. Earlier in his career, he was a Postdoctoral Research Fellow at the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania, from August 2010 to October 2012.
Honors & Awards:
Dr. Shen has garnered several prestigious honors and awards, including being a part of the Ad Hoc Young Editorial Board of the Journal of Molecular Cell Biology (JMCB) in 2020. Noteworthy accolades include the Harold C. and Mary L. Daily Endowment Award, the AMGEN Award in Basic Science, and a Postdoctoral Travel Award for Cancer Immunotherapy in 2018. In 2015, he received the “Science On The Wall” Award. During his student years, he earned Student Excellence Awards from the Graduate University of the Chinese Academy of Sciences in 2008. These accolades underscore his significant contributions to cancer research and immunotherapy.
Publications Top Noted & Contributions:
Dr. Shen has contributed significantly to cancer research with numerous publications in peer-reviewed journals. Notable contributions include insights into DNA repair mechanisms, immune responses, and the impact of chromatin remodeling on cancer progression. His work has been published in prestigious journals, such as Cancer Research, Nature Medicine, and Neoplasia.
F-box only protein 38 (FBXO38) in the regulation of the cyclic GMP–AMP synthase–stimulator of interferon genes (cGAS–STING) pathway, an important innate immune pathway that regulates type I interferons. Here is a breakdown of the key findings:
FBXO38 and Immune Regulation:
FBXO38 is a member of the F-box family known for mediating the ubiquitination and proteasome degradation of programmed death 1 (PD-1).
PD-1 is associated with T cell-related immunity.
Adaptive Immunity and Tumor Control:
FBXO38 plays a powerful role in adaptive immunity, particularly in the regulation of T cell-related immunity.
The deficiency of FBXO38 was found to enhance tumor proliferation and reduce the infiltration of CD8+ T cells into tumors.
FBXO38 and cGAS–STING Pathway:
The cGAS–STING pathway is crucial for regulating type I interferons, and STING is a core component of this pathway.
Impact of FBXO38 Deficiency on STING:
Loss of FBXO38 resulted in reduced levels of STING protein, both in vitro and in vivo.
The reduced STING levels led to the prevention of cGAS–STING pathway activation.
Downstream Effects of FBXO38 Deficiency:
The study observed decreased levels of downstream products of the cGAS–STING pathway, including IFNA1 and CCL5.
Mechanism of STING Reduction:
The reduction in STING protein levels was attributed to lysosome-mediated degradation rather than proteasomal function.
FBXO38’s Critical Role:
The study concludes that FBXO38 plays a critical role in the cGAS–STING pathway.
“FBXO38 deficiency promotes lysosome-dependent STING degradation and inhibits cGAS–STING pathway activation”
Neoplasia, March 2024
DOI: 10.1016/j.neo.2024.100973
Contributors: Yijia Wu, Yao Lin, Feiyang Shen, Rui Huang, Zhe Zhang, Min Zhou, Yan Fang, Jianfeng Shen, Xianqun Fan
“Structure prediction of novel isoforms from uveal melanoma by AlphaFold”
Scientific Data, August 4, 2023
DOI: 10.1038/s41597-023-02429-z
Contributors: Zhe Zhang, Chen Li, Qian Li, Xiaoming Su, Jiayi Li, Lili Zhu, Xinhua Lin, Jianfeng Shen
“Selamectin increases cisplatin sensitivity by inhibiting cisplatin-resistant genes expression and autophagy in uveal melanoma”
Biochemical and Biophysical Research Communications, June 2023
DOI: 10.1016/j.bbrc.2023.04.008
Contributors: Jie He, Jili Chen, Jianfeng Shen
“LIN28B inhibition sensitizes cells to p53-restoring PPI therapy through unleashed translational suppression”
Oncogenesis, July 2, 2022
DOI: 10.1038/s41389-022-00412-8
Contributors: Jiahao Shi, Xiaoliang Jin, Yihao Wang, Tianyu Zhu, Dongmei Zhang, Qian Li, Xiaomin Zhong, Yaqi Deng, Jianfeng Shen, Xianqun Fan
“PARP mediated DNA damage response, genomic stability and immune responses”
International Journal of Cancer, June 2022
DOI: 10.1002/ijc.33918
Contributors: Chunyan Zong, Tianyu Zhu, Jie He, Rui Huang, Renbing Jia, Jianfeng Shen
Research Timeline:
2005-2010: Pursued Ph.D. at the Chinese Academy of Sciences, focusing on Biochemistry and Molecular Biology.
2010-2012: Conducted postdoctoral research at the University of Pennsylvania, delving into DNA repair mechanisms.
2012-2019: Joined The University of Texas M.D. Anderson Cancer Center, contributing significantly as a Postdoctoral Research Fellow and later as an Instructor.
2019-present: Currently serving as a Principal Investigator and Assistant Professor at Shanghai Jiao Tong University School of Medicine, leading research efforts in cancer biology.
